Objective An antiretroviral regimen based on lamivudine+ stavudine+ protease inhibitor
impairs peripheral fat accrual in HIV-infected children and adolescents. We assess the effect …

BACKGROUND: The HIV-associated lipodystrophic syndrome (HIV-LDS) combines
redistribution of fat mass with insulin resistance and hyperlipidemia. We have previously …

Human immunodeficiency virus (HIV)-associated lipodystrophy syndrome (HALS) is a side
effect of highly active antiretroviral therapy of HIV-infected patients; however, the mechanism …

Context: The expression of adipogenic genes in sc adipose tissue has been reported to be
lower among patients with HIV-associated lipoatrophy than HIV-uninfected controls. It is …

Objective Despite evidence for the role of adipocyte-derived hormones in insulin resistance,
little is known about their levels in human lipodystrophic states. We examined the …

Objectives: To estimate the prevalence of and identify risk factors for lipodystrophy syndrome
(LS) and body fat abnormality in a population of HIV-infected children and adolescents …

HIV-infected patients on antiretroviral therapy frequently develop changes in body fat
distribution and disturbances in glucose metabolism, associated with reduced adiponectin …

Context: Lipodystrophy syndromes are characterized by generalized or partial absence of
adipose tissue. Objective: We conducted a systematic review to synthesize data on clinical …

Objective Circulating oestradiol and testosterone, which have been shown to increase in
human immunodeficiency virus (HIV)‐infected patients following highly active antiretroviral …

Background and Methods: HIV-infected patients receiving antiretroviral therapy often
develop changes in body fat distribution; the dominant change is reduction in sc adipose …